Company: NDRA
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001213900-25-110887
Chunk: 5

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 5
---
  
     -  
     -  
     -  
     -  
     (2,354,090) 
     (2,354,090)
  
    Balance as of September 30,
    2024 
     17.488  
    $-  
     -  
    $-  
     534,863  
    $53  
    $105,893,728  
    $-  
    $(99,289,095) 
    $6,604,686 

Three Months Ended September 30,2025

    Series A Convertible  
    Series B Convertible  

    Additional  

    Total 

    Preferred Stock  
    Preferred Stock  
    Common stock  
    Paid in  
    Stock  
    Accumulated  
    Stockholders’ 

    Shares  
    Amount  
    Shares  
    Amount  
    Shares  
    Amount  
    Capital  
    Payable  
    Deficit  
    Equity 
  
    Balance as of June 30, 2025 
     17.488  
    $-  
     -  
    $-  
     752,390  
    $74  
    $107,173,418  
     -  
    $(105,700,341) 
    $1,473,151 
  
    Common stock issued for cash 
     -  
     -  
     -  
     -  
     34,512  
     3  
     149,463  
     -  
     -  
     149,466 
  
    Fair value of vested stock options 
     -  
     -  
     -  
     -  
     -  
     -  
     39,957  
     -  
     -  
     39,957 
  
    Fair value of vested restricted stock units 
     -  
     -  
     -  
     -  
     -  
     -  
     104,765  
     -  
     -  
     104,765 
  
    Net loss 
     -  
     -